ADC Therapeutics (ADCT) Stock Forecast & Price Target

ADC Therapeutics is supported by its commercially approved ZYNLONTA franchise, which provides tangible cash flows and lowers regulatory risk versus a pre-revenue biotech, while its efficacy and potential expansion into additional indolent lymphomas keep the asset relevant to physicians. The company ended 2Q with $219M in cash and equivalents and maintained cash runway guidance into 2028, giving it enough balance-sheet flexibility to pursue earlier-line treatment opportunities after the 4Q25 capital raise. Although management reduced annualized costs by $10M through restructuring and recent LOTIS-5 results increased regulatory uncertainty, the core thesis remains intact because ZYNLONTA is already marketed and can still drive meaningful upside through broader penetration and pipeline execution.

ADC Therapeutics is facing a weak fundamental setup because its only marketed asset, ZYNLONTA, delivered just $18.6M in 2Q net sales, signaling limited commercial traction and an uncertain path to meaningful revenue inflection. The LOTIS-5 data only showed a modest PFS benefit (6.14 months vs. 4.73 months, HR 0.73) with no OS advantage (12.19 months vs. 12.16 months) and a concerning Grade 5 adverse-event imbalance (13.2% vs. 4.6%), which heightens regulatory and physician reluctance. Although LOTIS-7 has encouraging early response data, the company still faces substantial FDA risk, a crowded DLBCL landscape, and elevated dilution risk if growth and approvals do not materialize.